Skip to main content

01.09.2009 | Experimental Research | Ausgabe 9/2009

Acta Neurochirurgica 9/2009

CTNNB1 (β-catenin) mutation is rare in brain tumours but involved as a sporadic event in a brain metastasis

Acta Neurochirurgica > Ausgabe 9/2009
Chu-I Lee, Meng-Yu Hsu, Chia-Hua Chou, Chihuei Wang, Yu-Shung Lo, Joon-Khim Loh, Shen-Long Howng, Yi-Ren Hong
Wichtige Hinweise


Mutations that cause activation of the Wnt signalling pathway have been found in a proportion of medulloblastomas, embryonal tumours that most likely arise from granule cell precursors in the cerebellum. This includes mutations in CTNNB1, the gene encoding β-catenin. Interestingly, CTNNB1 mutations correlate with an improved prognosis for medulloblastoma patients. Tumourigenesis in these cases is believed to arise as a result of inappropriate activation of a pathway whose activity is normally restricted to the developing cerebellum. Lee et al have shown that activating mutations in CTNNB1 are rare in a number of other types of brain tumour, suggesting that many cell types in the CNS do not respond to activating Wnt signalling in the same way as granule cell precursors do. The identification of the mechanism underlying this difference will be important for understanding how different types of CNS tumours arise.
John Mason



The Wnt signaling pathway has been implicated in colon and other cancers. Nevertheless, few or no mutations of CTNNB1 (β-catenin) have so far been described in brain cancer. We therefore examined the prevalence of constitutive activation of the Wnt signaling pathway in brain cancer specimens as well as cancer cell lines.


We used polymerase chain reaction PCR and direct sequencing methods to investigate whether mutations in the CTNNB1 phosphorylation sites S33, S37, S41 and T45 were present in 68 brain tumours, including meningioma, astrocytoma, pituitary adenoma, neuroblastoma, metastasis to the brain, and cell lines.


CTNNB1 gene mutations were not found in either the original brain tumour specimens or the cell lines. However, a missense mutation of CTNNB1 was identified at residue 33, TCT (Ser) → TGT (Cys) in a patient with lung metastasis to brain. In addition, in vitro functional assay showed that the S33C mutant of β-catenin did affect transcriptional activity in a TCF-4-luciferase reporter construct.


These results indicate that the mutation of exon 3 of the CTNNB1 gene in brain tumours may be a rare event and yet may be required for a small subset of human metastatic brain tumours.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Über diesen Artikel

Weitere Artikel der Ausgabe 9/2009

Acta Neurochirurgica 9/2009 Zur Ausgabe
  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

  3. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Chirurgie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Chirurgie und bleiben Sie gut informiert – ganz bequem per eMail.